Publications by authors named "Pramod P Mehta"

Claim this Profile
R
Retraction notice to "A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells".
Pramod P Mehta, Pei-Pei Kung, Shinji Yamazaki, Marlena Walls, Andrea Shen

Cancer Lett· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3.
Rounak Nassirpour, Pramod P Mehta, Min-Jean Yin

PLoS One· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Marlena Walls, Sangita M Baxi, Pramod P Mehta, Kevin K-C Liu, Jinjiang Zhu

Clin Cancer Res· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miR-221 promotes tumorigenesis in human triple negative breast cancer cells.
Rounak Nassirpour, Pramod P Mehta, Sangita M Baxi, Min-Jean Yin

PLoS One· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
Jing Yuan, Pramod P Mehta, Min-Jean Yin, Shaoxian Sun, Aihua Zou

Mol Cancer Ther· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model.
Shinji Yamazaki, Leslie Nguyen, Sylvia Vekich, Zhongzhou Shen, Min-Jean Yin, Pramod P Mehta

J Pharmacol Exp Ther· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Pramod P Mehta, Pamela Whalen, Sangita M Baxi, Pei-Pei Kung, Shinji Yamazaki

Clin Cancer Res· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone.
Pei-Pei Kung, Piet-Jan Sinnema, Paul Richardson, Michael J Hickey, Ketan S Gajiwala, Pramod P Mehta

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
Luke Zehnder, Michael Bennett, Jerry Meng, Buwen Huang, Sacha Ninkovic, Pramod P Mehta

J Med Chem· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.
Pramod P Mehta, Pei-Pei Kung, Shinji Yamazaki, Marlena Walls, Andrea Shen

Cancer Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity.
Cathy C Zhang, Zhengming Yan, Qin Zhang, Kyle Kuszpit, Kenneth Zasadny, Pramod P Mehta

Clin Cancer Res· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.
Daniel P Becker, Thomas E Barta, Louis J Bedell, Terri L Boehm, Brian R Bond, Pramod P Mehta

J Med Chem· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solution-phase parallel synthesis of Hsp90 inhibitors.
Sujin Cho-Schultz, Monica Jo Patten, Buwen Huang, Jeff Elleraas, Ketan S Gajiwala, Pramod P Mehta

J Comb Chem· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.
Daniel P Becker, Clara I Villamil, Thomas E Barta, Louis J Bedell, Terri L Boehm, Pramod P Mehta

J Med Chem· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.
Thomas W Davis, Janet M O'Neal, Mark D Pagel, Ben S Zweifel, Pramod P Mehta

Cancer Res· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel benzothiazolesulfonamides as potent inhibitors of HIV-1 protease.
Srinivasan R Nagarajan, Gary A De Crescenzo, Daniel P Getman, Hwang Fun Lu, James A Sikorski, Pramod P Mehta

Bioorg Med Chem· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis